BioCentury
ARTICLE | Company News

New Zealand Pharmaceuticals, Fortress Biotech deal

August 24, 2015 7:00 AM UTC

New Zealand granted Fortress’ Altamira Bio subsidiary exclusive, worldwide rights to develop ManNAc to treat hereditary inclusion body myopathy (HIBM) and nephropathy. ManNAc was developed under a Co...